DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

The compound database

Peptide Database

264 therapeutic peptides with research summaries, clinical findings, and regulatory status. Every claim is cited.

FDA-approved
90
FDA-approved
Awaiting FDA
8
Awaiting FDA
No lawful pathway
166
No lawful pathway
1–36 of 264
  1. 001

    BPC-157

    A synthetic 15-amino acid peptide whose sequence is derived from a protein described in human gastric juice; it is not FDA approved. In rat and cell studies…

    Recovery · In Clinical Trials · Subcutaneous injection, Oral

    Awaiting FDA
  2. 002

    TB-500 (Thymosin Beta-4)

    Thymosin Beta-4 (Tβ4) is a 43-amino acid actin-sequestering protein involved in cell migration and tissue repair. Products sold as TB-500 have been found to…

    Recovery · Research Phase · Subcutaneous injection

    Awaiting FDA
  3. 003

    GHK-Cu

    A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine, with levels that decline with age. In…

    Recovery · In Clinical Trials · Topical, Subcutaneous injection

    No lawful pathway
  4. 004

    DSIP (Delta Sleep-Inducing Peptide)

    A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 from the cerebral venous blood of sleeping rabbits and initially proposed as a…

    Recovery · Investigational · Subcutaneous injection, Intravenous, Intranasal

    No lawful pathway
  5. 005

    Pentosan Polysulfate (Elmiron)

    A semi-synthetic sulfated polysaccharide (not a peptide) derived from beechwood hemicellulose, with structural similarity to glycosaminoglycans and heparin.…

    Recovery · FDA Approved · Oral

    FDA-approved
  6. 006

    Semaglutide (Ozempic/Wegovy)

    A glucagon-like peptide-1 receptor agonist (GLP-1 RA) that differs from native GLP-1 by two amino acid substitutions (about 94% sequence identity) plus a fatty…

    Metabolic · FDA Approved · Subcutaneous injection (weekly), Oral (daily - Rybelsus)

    FDA-approved
  7. 007

    Tirzepatide (Mounjaro/Zepbound)

    A once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways, and in…

    Metabolic · FDA Approved · Subcutaneous injection (weekly)

    FDA-approved
  8. 008

    Retatrutide

    An investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, not yet FDA approved. The glucagon receptor…

    Metabolic · In Clinical Trials · Subcutaneous injection (weekly)

    No lawful pathway
  9. 009

    AOD-9604

    A modified fragment of the C-terminus of human growth hormone, consisting of hGH residues 177-191 with an added N-terminal tyrosine (16 amino acids). AOD-9604…

    Metabolic · Investigational · Subcutaneous injection, Oral

    Awaiting FDA
  10. 010

    Liraglutide (Saxenda/Victoza)

    A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a 16-carbon fatty acid chain that binds albumin and protects against DPP-4…

    Metabolic · FDA Approved · Subcutaneous injection (daily)

    FDA-approved
  11. 011

    Exenatide (Byetta/Bydureon)

    A synthetic version of exendin-4, a 39-amino acid peptide originally isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide shares…

    Metabolic · FDA Approved · Subcutaneous injection (twice daily or weekly extended-release)

    FDA-approved
  12. 012

    Glucagon

    A 29-amino acid peptide hormone produced by alpha cells of the pancreatic islets of Langerhans. Glucagon acts on the liver via the glucagon receptor (GCGR), a…

    Metabolic · FDA Approved · Subcutaneous injection, Intramuscular injection, Intranasal

    FDA-approved
  13. 013

    Pramlintide (Symlin)

    A synthetic analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Pramlintide has…

    Metabolic · FDA Approved · Subcutaneous injection (before meals)

    FDA-approved
  14. 014

    Dulaglutide (Trulicity)

    A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog fused to a modified human IgG4 Fc fragment, a design that retained full receptor activity…

    Metabolic · FDA Approved · Subcutaneous injection (weekly)

    FDA-approved
  15. 015

    Lixisenatide (Adlyxin)

    A selective GLP-1 receptor agonist derived from exendin-4 with a modified C-terminal tail containing six lysine residues. Lixisenatide increases…

    Metabolic · FDA Approved · Subcutaneous injection (daily)

    FDA-approved
  16. 016

    Setmelanotide (Imcivree)

    A cyclic peptide melanocortin-4 receptor (MC4R) agonist designed to restore MC4R signaling in patients with obesity caused by genetic defects in the…

    Metabolic · FDA Approved · Subcutaneous injection (daily)

    FDA-approved
  17. 017

    CJC-1295

    A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to…

    Hormone · Investigational · Subcutaneous injection

    Awaiting FDA
  18. 018

    Ipamorelin

    A synthetic pentapeptide growth hormone secretagogue that acts on ghrelin/GHS receptors to stimulate GH release. In swine, ipamorelin released GH without…

    Hormone · Investigational · Subcutaneous injection

    Awaiting FDA
  19. 019

    Sermorelin

    A synthetic 29-amino acid analog of GHRH corresponding to the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates…

    Hormone · FDA Approved · Subcutaneous injection

    FDA-approved
  20. 020

    Tesamorelin (Egrifta)

    A synthetic GHRH analog consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve…

    Hormone · FDA Approved · Subcutaneous injection (daily)

    FDA-approved
  21. 021

    PT-141 (Bremelanotide / Vyleesi)

    A synthetic cyclic heptapeptide melanocortin receptor agonist structurally related to melanotan II. Unlike PDE5 inhibitors that act peripherally on vascular…

    Hormone · FDA Approved · Subcutaneous injection (as needed)

    FDA-approved
  22. 022

    Kisspeptin

    A family of neuropeptides encoded by the KISS1 gene that act as key upstream regulators of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin activates…

    Hormone · In Clinical Trials · Intravenous, Subcutaneous injection

    No lawful pathway
  23. 023

    Oxytocin

    A nine-amino acid cyclic neuropeptide produced mainly in the hypothalamus and released from the posterior pituitary in response to stimuli such as suckling…

    Hormone · FDA Approved · Intravenous, Intramuscular injection, Intranasal

    FDA-approved
  24. 024

    GHRP-2

    A synthetic hexapeptide growth hormone secretagogue (also called pralmorelin) that acts on the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary to…

    Hormone · Investigational · Subcutaneous injection, Intravenous

    No lawful pathway
  25. 025

    GHRP-6

    A synthetic hexapeptide growth hormone secretagogue that stimulates GH release via the ghrelin receptor (GHS-R1a). In healthy men, most of its GH-releasing…

    Hormone · Investigational · Subcutaneous injection, Intravenous

    No lawful pathway
  26. 026

    Hexarelin

    A synthetic hexapeptide growth hormone secretagogue that causes profound GH release in humans after oral, intranasal, intravenous or subcutaneous…

    Hormone · Investigational · Subcutaneous injection, Intravenous

    No lawful pathway
  27. 027

    MK-677 (Ibutamoren)

    An orally active, non-peptide growth hormone secretagogue that mimics ghrelin at the GHS-R1a receptor. In healthy older adults, once-daily oral MK-677…

    Hormone · In Clinical Trials · Oral

    No lawful pathway
  28. 028

    Macimorelin (Macrilen)

    An orally active ghrelin mimetic and growth hormone secretagogue developed as a diagnostic agent for adult growth hormone deficiency (AGHD). Macimorelin…

    Hormone · FDA Approved · Oral

    FDA-approved
  29. 029

    Cosyntropin (Cortrosyn)

    A synthetic peptide consisting of the first 24 amino acids of the 39-amino acid adrenocorticotropic hormone (ACTH). Cosyntropin reproduces the…

    Hormone · FDA Approved · Intravenous, Intramuscular injection

    FDA-approved
  30. 030

    Gonadorelin (GnRH)

    A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone. A pulsatile pattern of GnRH is required for pituitary stimulation and release…

    Hormone · FDA Approved · Intravenous, Subcutaneous injection

    FDA-approved
  31. 031

    Leuprolide (Lupron)

    A synthetic nonapeptide GnRH agonist that is more potent and longer-acting than native GnRH. After an initial stimulatory phase (flare effect), chronic…

    Reproductive · FDA Approved · Subcutaneous injection, Intramuscular injection (depot)

    FDA-approved
  32. 032

    Goserelin (Zoladex)

    A synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other…

    Reproductive · FDA Approved · Subcutaneous implant

    FDA-approved
  33. 033

    Cetrorelix (Cetrotide)

    A synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, rapidly suppressing LH and FSH without the initial flare effect…

    Reproductive · FDA Approved · Subcutaneous injection

    FDA-approved
  34. 034

    Ganirelix

    A synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells. GnRH antagonists such as…

    Reproductive · FDA Approved · Subcutaneous injection

    FDA-approved
  35. 035

    Carbetocin

    A long-acting synthetic analog of oxytocin with structural modifications that confer resistance to enzymatic degradation. Carbetocin has a longer half-life and…

    Reproductive · In Clinical Trials · Intravenous, Intramuscular injection

    No lawful pathway
  36. 036

    Atosiban

    A competitive oxytocin/vasopressin V1a receptor antagonist used outside the US as a tocolytic agent to delay preterm labor. Atosiban blocks oxytocin-mediated…

    Reproductive · In Clinical Trials · Intravenous

    No lawful pathway

Index · all 264 peptides, A–Z

Important Medical Disclaimer

The information provided by the Peptide Association is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified, licensed healthcare provider before beginning any peptide therapy, supplement regimen, or making changes to an existing treatment plan.

Peptide therapies discussed on this site may not be FDA-approved for all listed indications. Individual results vary. The Peptide Association does not prescribe, diagnose, or treat any medical condition. Clinicians in our network are independently licensed practitioners; the Association checks each clinician’s NPI record but does not employ or directly supervise these clinicians.

© 2026 The Peptide Association. All rights reserved. Content on this site is protected under applicable intellectual property laws. The Peptide Association is not a medical practice.